| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
H-Phe-Trp-OH is an endogenous metabolite that does not have a well-defined specific therapeutic target. As a dipeptide, it is a product of protein degradation and is involved in protein synthesis and metabolism. The compound may interact with various peptide transporters and enzymes involved in peptide metabolism. Its aromatic amino acid composition (phenylalanine and tryptophan) contributes to its interactions in biological systems.
|
|---|---|
| ln Vitro |
H-Phe-Trp-OH is an endogenous metabolite involved in protein synthesis and metabolism. As a dipeptide, it is a breakdown product of proteins containing phenylalanine and tryptophan residues. The compound's structural characteristics include a hydrophobic core due to the aromatic side chains. It is used in research as a model dipeptide for studying peptide chemistry, metabolism, and transport. The compound may also be used in studies of peptide-protein interactions.
|
| ln Vivo |
In vivo, H-Phe-Trp-OH is an endogenously produced metabolite that participates in protein metabolism. It is formed during protein degradation and can be further metabolized to its constituent amino acids. The compound is not used as a therapeutic agent but is studied for its role in metabolism and peptide transport. Specific in vivo efficacy studies are not applicable, as the compound is a metabolic product rather than a drug. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro assays for H-Phe-Trp-OH typically involve its use as a substrate or standard in enzymatic or metabolic studies. The compound can be incubated with peptidases or proteases to study peptide cleavage and metabolism. The reaction products are analyzed by HPLC or mass spectrometry. The compound is dissolved in appropriate buffers (such as PBS or Tris-HCl) and incubated at physiological pH and temperature. Standard analytical methods include HPLC, LC-MS, and amino acid analysis.
|
| Cell Assay |
In vitro cellular assays for H-Phe-Trp-OH typically involve treating cells with the dipeptide to study peptide uptake and metabolism. Cells are incubated with the compound at concentrations ranging from 1 to 100 μM for various time periods. Peptide uptake is assessed by measuring intracellular peptide or amino acid levels by HPLC or mass spectrometry. The compound is dissolved in DMSO or water as a stock solution and diluted in cell culture medium. Peptide transporter activity can be assessed using specific transporter inhibitors.
|
| Animal Protocol |
In vivo animal studies for H-Phe-Trp-OH are not typically performed, as the compound is an endogenous metabolite rather than a therapeutic agent. The compound may be used in metabolic studies to trace peptide metabolism in vivo, but specific protocols are not well-established. The compound is not intended for human therapeutic use. Standard metabolic studies would involve administration of labeled or unlabeled compound and analysis of blood, urine, and tissue samples.
|
| ADME/Pharmacokinetics |
H-Phe-Trp-OH has a molecular weight of 351.4 g/mol and formula C20H21N3O3. It is an endogenous metabolite. Recommended storage is at 4°C, protected from light. In solvent, storage at -80°C for 6 months or at -20°C for 1 month, protected from light. Purity is ≥98%. The compound is soluble in DMSO and other organic solvents. Detailed PK parameters are not applicable for this endogenous metabolite.
|
| Toxicity/Toxicokinetics |
H-Phe-Trp-OH is intended for research use only and is not approved for human therapeutic applications. As an endogenous metabolite, it is generally considered to have low toxicity. Appropriate safety precautions should be taken when handling, including wearing gloves and protective eyewear. Standard toxicity assessments would include acute toxicity and repeated-dose toxicity studies if required for specific applications. The compound is not intended for human consumption.
|
| References | |
| Additional Infomation |
Phenylalanine-tryptophan (Phe-Trp) is a dipeptide formed from L-phenylalanine and L-tryptophan residues, and it is a metabolite.
H-Phe-Trp-OH (CAS 24587-41-5) is a linear dipeptide composed of L-phenylalanine and L-tryptophan. It has a molecular weight of 351.4 g/mol and formula C20H21N3O3. The compound is an endogenous metabolite involved in protein synthesis and metabolism. It is also known as L-Phenylalanyl-L-tryptophan and phenylalanyltryptophan. The compound is not approved for clinical use. |
| Molecular Formula |
C20H21N3O3
|
|---|---|
| Molecular Weight |
351.39904
|
| Exact Mass |
351.158
|
| CAS # |
24587-41-5
|
| PubChem CID |
134906
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
688.3±55.0 °C at 760 mmHg
|
| Flash Point |
370.1±31.5 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.672
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
26
|
| Complexity |
493
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N
|
| InChi Key |
JMCOUWKXLXDERB-WMZOPIPTSA-N
|
| InChi Code |
InChI=1S/C20H21N3O3/c21-16(10-13-6-2-1-3-7-13)19(24)23-18(20(25)26)11-14-12-22-17-9-5-4-8-15(14)17/h1-9,12,16,18,22H,10-11,21H2,(H,23,24)(H,25,26)/t16-,18-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~284.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8458 mL | 14.2288 mL | 28.4576 mL | |
| 5 mM | 0.5692 mL | 2.8458 mL | 5.6915 mL | |
| 10 mM | 0.2846 mL | 1.4229 mL | 2.8458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
